13 Diabetics Implanted with VeriMed RFID Microchip at Boston Diabetes EXPO.VeriChip Corporation VeriChip Corporation, a wholly owned subsidiary of Applied Digital (Nasdaq: ADSX), markets a line of Radio Frequency Identification (RFID) Devices (including VeriChip) used in security, financial, emergency identification, and other applications. continues to focus on diabetic patients to provide important identification and medical record information DELRAY BEACH Delray Beach, resort city (1990 pop. 47,181), Palm Beach co., SE Fla., on the Atlantic coast; settled 1895, inc. 1911. Mostly residential, Delray Beach is also the trade center for a citrus-fruit and vegetable-growing region. , Fla., March 19 /PRNewswire-FirstCall/ -- VeriChip Corporation , a provider of RFID (Radio Frequency IDentification) A data collection technology that uses electronic tags for storing data. The tag, also known as an "electronic label," "transponder" or "code plate," is made up of an RFID chip attached to an antenna. systems for healthcare and patient-related needs, announced today it added 13 diabetic patients to its VeriMed Patient Identification System network at a Boston Diabetes EXPO sponsored by the American Diabetes Association (ADA). At the Boston Diabetes EXPO, physicians implanted im·plant v. im·plant·ed, im·plant·ing, im·plants v.tr. 1. To set in firmly, as into the ground: implant fence posts. 2. VeriMed RFID microchips in conference attendees who signed up for the voluntary procedure. The VeriMed Patient Identification System, which utilizes an implantable RFID microchip (1) Another term for a microminiaturized integrated circuit (a "chip"). (2) To insert an RFID tag beneath the skin of an animal. It is expected that some day, humans will be microchipped. in combination with a handheld RFID scanner and a secure patient database, provides immediate access to important identification and health information for patients who arrive at an emergency department unable to communicate. Scott R. Silverman, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of VeriChip, commented, "We continue to expand our presence at ADA events and focus on individuals with diabetes as we believe they, and other high-risk populations, may benefit greatly from the VeriMed Patient Identification System. Through the Atlanta and Boston Diabetes EXPOs, we have now enrolled 31 more patients in our system. Furthermore, these sign-ups by diabetic individuals underscore The underscore character (_) is often used to make file, field and variable names more readable when blank spaces are not allowed. For example, NOVEL_1A.DOC, FIRST_NAME and Start_Routine. (character) underscore - _, ASCII 95. the importance of our planned future development efforts to commercialize a glucose-sensing implantable microchip, with our sister company Digital Angel, which was awarded a patent on this breakthrough product." The Diabetes EXPO is a patient-driven tradeshow, including professional speakers and a variety of ADA program/event information, where exhibitors from pharmaceutical and medical device companies display beneficial products for diabetics. The Diabetes EXPO began in 1995 in Phoenix, Arizona Phoenix /ˈfiːˌnɪks/ (English: Phoenix, Navajo: Hoozdo, lit. "the place is hot", Western Apache: Fiinigis) is the capital and the most populous city of the U.S. , and has grown to 18, metro, major and mid-size cities around the U.S. The next event will be held in Chicago on April 28, 2007. About VeriChip Corporation VeriChip Corporation, headquartered in Delray Beach, Florida Delray Beach is a city in Palm Beach County, Florida, USA. As of the 2000 census, the city had a total population of 60,020. As of 2004, the population estimated by the U.S. Census Bureau is 64,150. , develops, markets and sells radio frequency identification See RFID. , or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. VeriChip sells passive RFID systems for identification purposes and active RFID systems for local-area location and identification purposes. VeriChip recently began to market its VeriMed(TM) Patient Identification System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. . VeriChip Corporation is majority-owned by Applied Digital Inc. , which also owns a majority position in Digital Angel Corporation . For more information on VeriChip, please call 1-800-970- 2447, or email info@verichipcorp.com. Additional information can be found online at http://www.verichipcorp.com/. Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. VeriChip Corporation , a provider of RFID systems for healthcare and patient-related needs, announced today it added 18 diabetic patients to its VeriMed Patient Identification System at an Atlanta Diabetes EXPO sponsored by the American Diabetes Association (ADA). At the EXPO, physicians implanted VeriMed RFID microchips in conference attendees who signed up for the voluntary procedure. The VeriMed Patient Identification System, which utilizes an implantable RFID microchip in combination with a handheld RFID scanner and a secure patient database, provides immediate access to important health information for patients who arrive at an emergency department unable to communicate. Scott R. Silverman, Chairman and CEO of VeriChip, commented "We believe the VeriMed Patient Identification System is an essential health care solution for at-risk patients, including diabetics, who tend to present with various co-morbidities and medications, and are more frequently admitted to emergency departments. The ADA Diabetes EXPO provides us direct access so we can continue to educate an important target audience." The Expo is a patient-driven tradeshow, including professional speakers and a variety of ADA program/event information, where exhibitors from pharmaceutical and medical device companies display beneficial products for diabetics. The Diabetes EXPO began in 1995 in Phoenix, Arizona, and has grown to 18, metro, major and mid-size cities around the U.S. The next event will be held in Boston on March 17. About VeriChip Corporation VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. VeriChip sells passive RFID systems for identification purposes and active RFID systems for local-area location and identification purposes. VeriChip recently began to market its VeriMed(TM) Patient Identification System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration. VeriChip Corporation is majority-owned by Applied Digital Inc. , which also owns a majority position in Digital Angel Corporation . For more information on VeriChip, please call 1-800-970-2447, or email info@verichipcorp.com. Additional information can be found online at http://www.verichipcorp.com/. Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Contact: VeriChip Corporation Allison Tomek 561-805-8000 atomek@adsx.com The Ruth Group Nick Laudico (investors) (646) 536-7030 nlaudico@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com CONTACT: VeriChip Corporation, Allison Tomek, +1-561-805-8000, atomek@adsx.com; The Ruth Group, Nick Laudico (investors), +1-646-536-7030, nlaudico@theruthgroup.com, or Jason Rando (media), +1-646-536-7025, jrando@theruthgroup.com Web site: http://www.verichipcorp.com/ |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion